Keyword: Boehringer Ingelheim
An SGLT2 arms race is currently underway for heart failure patients, and not without reason: the market will likely continue to boom this decade.
Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.
Boehringer Ingelheim's leap of faith in China has paid off with the German company's production of a PD-1 for BeiGene.
With a nod in heart failure patients already secured, AstraZeneca's Farxiga has now landed a priority review in patients with or without diabetes.
Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.
Boehringer Ingelheim has recruited label design and management specialist NiceLabel to develop a global standardized labeling process.
In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.
Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.
Eli Lilly and Boehringer Ingelheim failed to persuade an FDA expert panel that their SGLT2 med, Jardiance, could be repurposed for Type 1 diabetes.
Lilly and BI have taken the leading position with Jardiance, and now the partners are changing their 2011 alliance agreement to focus on the drug.